Amisulpride (Amisulpride Sandoz Pharma)
Amisulpride risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Amisulpride Sandoz Pharma, AMISULPRIDE-WGR, Solian 100, Sulprix, APO-Amisulpride and 3 more.
Amisulpride (brand names: Amisulpride Sandoz Pharma, AMISULPRIDE-WGR, Solian 100, Sulprix, APO-Amisulpride and 3 more) is classified as Moderate risk (4 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Antipsychotic with significant CNS depression and extrapyramidal side effects affecting motor function.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Moderate (4 points)
- CNS depressant: May cause sedation, impair driving, and affect work capacity
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
Antipsychotic with significant CNS depression and extrapyramidal side effects affecting motor function.
Regulatory and Compliance Guidance
When Amisulpride appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Work capacity impact: As a CNS depressant, Amisulpride may impair driving, operating machinery, and cognitive function. Work capacity certificates should reflect any medication-related restrictions.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Need to assess this medication across your caseload?
Run a full risk assessment including Amisulpride interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.